GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) had its price target reduced by Argus from $95.00 to $80.00 in a report released on Tuesday,MarketScreener reports. The firm currently has a “buy” rating on the stock. Argus’ price target would suggest a potential upside of 29.01% from the stock’s current price.
GEHC has been the subject of a number of other reports. BTIG Research decreased their target price on GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Stifel Nicolaus set a $80.00 price target on GE HealthCare Technologies in a research report on Wednesday, April 29th. Weiss Ratings downgraded GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday. Jefferies Financial Group decreased their price target on shares of GE HealthCare Technologies from $105.00 to $90.00 in a research note on Thursday, April 30th. Finally, The Goldman Sachs Group lowered GE HealthCare Technologies from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $81.00 to $65.00 in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $80.63.
Get Our Latest Stock Analysis on GEHC
GE HealthCare Technologies Price Performance
GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.04 billion. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Research analysts expect that GE HealthCare Technologies will post 4.89 EPS for the current year.
Insider Activity
In other GE HealthCare Technologies news, Director Rodney F. Hochman acquired 1,618 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were bought at an average price of $62.03 per share, with a total value of $100,364.54. Following the transaction, the director directly owned 1,618 shares of the company’s stock, valued at $100,364.54. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Watkin Phoebe L. Yang bought 1,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were acquired at an average price of $63.01 per share, with a total value of $63,010.00. Following the completion of the transaction, the director owned 13,702 shares of the company’s stock, valued at approximately $863,363.02. The trade was a 7.87% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 11,847 shares of company stock worth $719,555 in the last three months. Corporate insiders own 0.36% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Auto Owners Insurance Co grew its holdings in GE HealthCare Technologies by 9,525.4% in the fourth quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after purchasing an additional 33,629,559 shares during the last quarter. Norges Bank purchased a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at $596,024,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of GE HealthCare Technologies in the 4th quarter worth $533,655,000. Capital Research Global Investors grew its stake in GE HealthCare Technologies by 25.0% during the 3rd quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock worth $1,875,400,000 after buying an additional 4,998,154 shares during the last quarter. Finally, Cynosure Group LLC grew its stake in GE HealthCare Technologies by 21,045.4% during the 4th quarter. Cynosure Group LLC now owns 4,365,462 shares of the company’s stock worth $358,055,000 after buying an additional 4,344,817 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.
About GE HealthCare Technologies
GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.
Featured Articles
- Five stocks we like better than GE HealthCare Technologies
- Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings
- Rewiring AI: NextEra Energy Sparks a Mega Merger
- Flipping the Switch: Is Ford the Next Big Energy Stock?
- Does Nano Nuclear Energy’s New Deal Amp the Outlook?
Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
